We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+56.41%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$458M
AUM Growth
+$199M
Cap. Flow
+$84.3M
Cap. Flow %
18.42%
Top 10 Hldgs %
84.01%
Holding
34
New
6
Increased
5
Reduced
2
Closed
3

Top Buys

Rank Stock Value
1
ESPR
Esperion Therapeutics
ESPR
+$29.2M
2
PTCT icon
PTC Therapeutics
PTCT
+$18.2M
3
MDCO
Medicines Co
MDCO
+$17.6M
4
CLVS
Clovis Oncology, Inc.
CLVS
+$9.12M
5
LJPC
La Jolla Pharmaceutical Company
LJPC
+$4.27M

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$4.71M
2
ARRY
Array Biopharma Inc
ARRY
+$1.76M
3
RXDX
Ignyta, Inc.
RXDX
+$663K
4
AKTX
Akari Therapeutics
AKTX
+$314K
5
ARDM
Aradigm Corp Common Stock
ARDM
+$109K

Sector Composition

Rank Sector Weight
1 Healthcare 79.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVXS
1
DELISTED
AveXis, Inc. Common Stock
AVXS
$78.2M 17.09%
1,028,763
– –
CLVS
2
DELISTED
Clovis Oncology, Inc.
CLVS
$63.7M 13.91%
1,000,000
+150,000
+18% +$9.12M
MDCO
3
DELISTED
Medicines Co
MDCO
$59.4M 12.98%
1,215,000
+386,802
+47% +$17.6M
ESPR
4
DELISTED
Esperion Therapeutics
ESPR
$45M 9.84%
+1,275,000
New +$29.2M
MDCO
5
CALL
DELISTED
Medicines Co
MDCO
$33.4M 7.31%
683,700
+56,300
+9% +$2.57M
ONC
6
BeOne Medicines Ltd
ONC
$32.8B
$31.1M 6.8%
850,000
– –
BPMC
7
DELISTED
Blueprint Medicines
BPMC
$30.8M 6.73%
770,159
+65,000
+9% +$2.33M
PTCT icon
8
PTC Therapeutics
PTCT
$5.64B
$14.8M 3.23%
+1,500,000
New +$18.2M
NGNE icon
9
Neurogene
NGNE
$656M
$14.7M 3.2%
43,888
– –
INCY icon
10
Incyte
INCY
$24.2B
$13.4M 2.92%
100,000
– –
ALNY icon
11
Alnylam Pharmaceuticals
ALNY
$27.5B
$12.8M 2.8%
250,000
– –
ALXN
12
DELISTED
Alexion Pharmaceuticals
ALXN
$9.09M 1.99%
75,000
– –
SGEN
13
DELISTED
Seagen Inc. Common Stock
SGEN
$6.29M 1.37%
100,000
– –
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$5.4M 1.18%
1,037,994
+280,059
+37% +$1.53M
LJPC
15
DELISTED
La Jolla Pharmaceutical Company
LJPC
$5M 1.09%
+167,400
New +$4.27M
KURA icon
16
Kura Oncology
KURA
$800M
$4.69M 1.03%
533,251
– –
SBBP
17
DELISTED
Strongbridge Biopharma plc.
SBBP
$4.46M 0.98%
940,000
– –
PBYI icon
18
Puma Biotechnology
PBYI
$404M
$3.72M 0.81%
+100,000
New +$3.65M
CBAY
19
DELISTED
Cymabay Therapeutics
CBAY
$3.34M 0.73%
+777,202
New +$2.23M
SNDX icon
20
Syndax Pharmaceuticals
SNDX
$1.69B
$3.21M 0.7%
234,220
– –
BLPH
21
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$2.77M 0.6%
123,810
– –
VIRX
22
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.15M 0.47%
15,000
– –
NBRV
23
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$2.12M 0.46%
707
– –
EIGR
24
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.58M 0.35%
4,611
– –
ALDX icon
25
Aldeyra Therapeutics
ALDX
$92.9M
$1.46M 0.32%
291,230
– –
1
2

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q1 2017 Portfolio in Review

As of Q1 2017, Boxer Capital held 34 positions worth $458M, up 77% from $259M the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Boxer Capital deployed $84.3M of net new capital in Q1 2017, opening 6 new positions and adding to 5 existing holdings. Its largest new stake was Esperion Therapeutics: 1,275,000 shares worth $45M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 80% a quarter earlier.

On the sell side, the largest reduction was Akari Therapeutics, an estimated $314K trimmed.

  • Boxer Capital's largest Q1 2017 buy was Esperion Therapeutics: 1,275,000 shares worth $45M.
  • Boxer Capital added most to Medicines Co in Q1 2017, an estimated $17.6M increase.
  • Boxer Capital's biggest Q1 2017 reduction was Akari Therapeutics, cutting an estimated $314K.
  • Boxer Capital fully exited TESARO, Inc. in Q1 2017, selling an estimated $4.71M.
  • Boxer Capital's ten largest holdings make up 84% of its $458M portfolio in Q1 2017.
  • Boxer Capital opened 6 new positions and closed 3 in Q1 2017.
  • Boxer Capital's portfolio value rose 77% quarter-over-quarter to $458M.

Based on Boxer Capital's 13F filing for Q1 2017, filed 15 May 2017.